Therapeutic radiopharmaceutical developer IsoRay Medical reported that the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, and Arizona Oncology Services (AOS) of Phoenix are two of the latest medical facilities offering prostate cancer patients the company’s Proxcelan brachytherapy seeds, a proprietary cesium-131 formulation.

Proxcelan has U.S. Food and Drug Administration 510(k) clearance for treating prostate cancer and other malignancies.

The UPMC facility encompasses 19 hospitals and 40 cancer centers with 75 affiliated oncologists and AOS serves more than 4,000 patients annually, according to the Richland, Wash.-based IsoRay.